SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

por Moyo-Gwete, Thandeka, Madzivhandila, Mashudu, Makhado, Zanele, Ayres, Frances, Mhlanga, Donald, Oosthuysen, Brent, Lambson, Bronwen E., Kgagudi, Prudence, Tegally, Houriiyah, Iranzadeh, Arash, Doolabh, Deelan, Tyers, Lynn, Chinhoyi, Lionel R., Mennen, Mathilda, Skelem, Sango, Marais, Gert, Wibmer, Constantinos Kurt, Bhiman, Jinal N, Ueckermann, Veronica, Rossouw, Theresa, Boswell, Michael, de Oliveira, Tulio, Williamson, Carolyn, Burgers, Wendy A, Ntusi, Ntobeko, Morris, Lynn, Moore, Penny L
Publicado 2021

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

por Moyo-Gwete, Thandeka, Madzivhandila, Mashudu, Makhado, Zanele, Ayres, Frances, Mhlanga, Donald, Oosthuysen, Brent, Lambson, Bronwen E., Kgagudi, Prudence, Tegally, Houriiyah, Iranzadeh, Arash, Doolabh, Deelan, Tyers, Lynn, Chinhoyi, Lionel R., Mennen, Mathilda, Skelem, Sango, Marais, Gert, Wibmer, Constantinos K., Bhiman, Jinal N., Ueckermann, Veronica, Rossouw, Theresa, Boswell, Michael, de Oliveira, Tulio, Williamson, Carolyn, Burgers, Wendy A., Ntusi, Ntobeko, Morris, Lynn, Moore, Penny L.
Publicado 2021